Karyopharm announces fda approval of xpovio (selinexor) for treatment of patients with relapsed or refractory diffuse large b-cell lymphoma

Karyopharm announces fda approval of xpovio® (selinexor) for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl).karyopharm therapeutics - marketing authorization application for selinexor for relapsed or refractory dlbcl planned for submission to european medicines agency in 2021.karyopharm therapeutics inc - xpovio will be commercially available immediately in new indication in u.s..
KPTI Ratings Summary
KPTI Quant Ranking